@article{3817b3cdd8904fcc906e780ec2d9db37,
title = "Management of IBD patients during the COVID-19 pandemic",
author = "Hanauer, {Stephen B.} and Lichtenstein, {Gary R.}",
note = "Funding Information: Dr Lichtenstein has consulted for AbbVie, American Regent, Celgene, CellCeutix, Eli Lilly, Endo Pharmaceuticals, Ferring, Gilead, Janssen Orthobiotech, Merck, Morphic Therapeutics, Pfizer Pharmaceuticals, Prometheus Laboratories, Romark, Salix Pharmaceuticals/Valeant, Shire Pharmaceuticals, Takeda, and UCB; conducted research for Celgene, Janssen Orthobiotech, and UCB; served on the DSMB for Eli Lilly; received honorarium (CME program) from American Regent, Merck, and Romark; and received funding to the University of Pennsylvania (IBD fellow education) from Janssen Orthobiotech, Pfizer Pharmaceuticals, and Takeda.",
year = "2020",
month = nov,
language = "English (US)",
volume = "16",
pages = "577--580",
journal = "Gastroenterology and Hepatology",
issn = "1554-7914",
publisher = "Gastro-Hep Communications, Inc.",
number = "11",
}